company background image
6978

Immunotech Biopharm SEHK:6978 Stock Report

Last Price

HK$4.21

Market Cap

HK$2.2b

7D

24.2%

1Y

-73.7%

Updated

27 Sep, 2022

Data

Company Financials
6978 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

6978 Stock Overview

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China.

Immunotech Biopharm Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immunotech Biopharm
Historical stock prices
Current Share PriceHK$4.21
52 Week HighHK$17.50
52 Week LowHK$3.21
Beta1.57
1 Month Change2.93%
3 Month Change-21.16%
1 Year Change-73.69%
3 Year Changen/a
5 Year Changen/a
Change since IPO-72.80%

Recent News & Updates

Dec 30
Will Immunotech Biopharm (HKG:6978) Spend Its Cash Wisely?

Will Immunotech Biopharm (HKG:6978) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

6978HK BiotechsHK Market
7D24.2%-2.7%-3.9%
1Y-73.7%-58.8%-25.9%

Return vs Industry: 6978 underperformed the Hong Kong Biotechs industry which returned -60.5% over the past year.

Return vs Market: 6978 underperformed the Hong Kong Market which returned -25.2% over the past year.

Price Volatility

Is 6978's price volatile compared to industry and market?
6978 volatility
6978 Average Weekly Movement14.7%
Biotechs Industry Average Movement8.3%
Market Average Movement6.3%
10% most volatile stocks in HK Market12.6%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 6978 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: 6978's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2006268Wang Yuhttps://www.eaal.net

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer.

Immunotech Biopharm Ltd Fundamentals Summary

How do Immunotech Biopharm's earnings and revenue compare to its market cap?
6978 fundamental statistics
Market CapHK$2.17b
Earnings (TTM)-HK$381.74m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
6978 income statement (TTM)
RevenueCN¥0
Cost of RevenueCN¥0
Gross ProfitCN¥0
Other ExpensesCN¥347.26m
Earnings-CN¥347.26m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.67
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.1%

How did 6978 perform over the long term?

See historical performance and comparison